# High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease

> **NCT01200329** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 81 (actual)

## Conditions studied

- Lymphoma

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Busulfan
- **DRUG:** Melphalan
- **PROCEDURE:** Stem Cell Transplantation
- **DRUG:** Palifermin

## Key facts

- **NCT ID:** NCT01200329
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-06
- **Primary completion:** 2018-12-06
- **Final completion:** 2018-12-06
- **Target enrollment:** 81 (ACTUAL)
- **Last updated:** 2019-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01200329

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01200329, "High-Dose Gemcitabine, Busulfan and Melphalan for Patients With Refactory Hodgkin's Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01200329. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*